查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1701384

美国兽医癌症诊断市场规模、份额、趋势分析报告（按动物类型、检测类型、癌症类型、最终用途、国家/地区、细分市场预测），2025 年至 2030 年

U.S. Veterinary Oncology Diagnostics Market Size, Share & Trends Analysis Report By Animal Type (Canine, Feline), By Test Type (Biopsy, Genome Testing), By Cancer Type (Skin Cancers, Sarcomas), By End Use, By Country, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国兽医癌症诊断市场的成长与趋势：

根据 Grand View Research, Inc. 的一份新报告，美国兽医癌症诊断市场预计到 2030 年将达到 16 亿美元，2025 年至 2030 年的复合年增长率为 8.55%。

市场的主要驱动因素包括动物数量和圈养率的上升、动物支出的增加、对预防性动物保健的日益关注，以及主要企业之间为扩大产品供应而不断加强的伙伴关係。例如，2025 年 2 月，Torigen Pharmaceuticals 和 Proscia 合作利用人工智慧数位病理学更快、更准确地诊断宠物的癌症。这可以实现更快、更个人化的免疫治疗，并提高转移性血管肉瘤犬的存活率。 Torigen 的人工智慧诊断将显着提高癌症检测的准确性和速度。 3-5 天内提供结果可缩短诊断週转时间，使兽医能够更快地开始标靶治疗。这项技术创新预计将推动兽医肿瘤学对数位病理解决方案的需求，从而促进市场成长。

此外，兽医癌症诊断测试​​的进步以及动物健康诊断研发投资的增加以推出创新产品正在推动市场成长。例如，2024年12月，Pet Preferred Diagnostics宣布推出一项针对猫狗的突破性早期癌症诊断测试​​，可检测与21种肿瘤和14种神经系统疾病相关的11种特异性肿瘤抗体。这种高度敏感的血清学检测通常能够在临床症状出现之前发现恶性肿瘤，从而实现早期治疗。该测试是兽医学中唯一能够区分多种肿瘤和神经系统疾病的测试，并且是非侵入性的、价格实惠的，并且可以在 24 小时内提供快速解决方案并得出结果。

宠物癌症发生率的上升是美国兽医癌症诊断市场的主要驱动力，每年有四分之一的狗和五分之一的猫被诊断出罹患癌症。随着饲主寻求早期发现和个人化治疗，宠物拥有的增加和人性化趋势正在推动对先进诊断的需求。液态切片测试（例如 PetDx 的 OncoK9）和人工智慧数位病理测试（例如 Torigen 与 Proscia 的合作）等技术进步正在提高诊断的准确性和效率。此外，价格实惠的家庭癌症筛检测试（如 Oncotect）的普及使得早期诊断更加容易，从而进一步促进了市场的成长。

美国兽医癌症诊断市场报告重点

  • 根据测试类型，切片检查部分占据市场主导地位，2024 年的份额为 28.75%。然而，由于兽医癌症诊断检测套组的技术进步，基因组测试部分预计将以最快的速度成长，预测期内的复合年增长率为 9.62%。
  • 根据动物类型，预计狗类将在 2024 年占据最大的收益占有率，这是由于狗的癌症数量不断增加，并且有大量用于狗癌症诊断的产品可供选择。由于全球猫科动物数量的增加以及相关疾病的显着增加，预计 2025 年至 2030 年间猫科动物市场将以最快的速度成长。
  • 根据癌症类型，皮肤癌部分预计将在 2024 年占据最高收益占有率，并以 8.71% 的最快复合年增长率增长，这归因于狗和猫鳞状细胞癌和皮肤肿瘤患病率的上升。
  • 根据最终用途，由于医院对诊断的需求不断增加以及易于获得的先进动物癌症诊断技术，兽医医院和诊所部门预计将在 2024 年占据市场的最高收入份额。预计未来几年该领域将以最快的复合年增长率成长。
  • 随着创新液态切片和先进的多癌症诊断技术的发展，兽医癌症诊断检测套组变得更加准确、易于使用和具有成本效益。预计这些进步将推动市场成长。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国兽医癌症诊断市场的趋势与展望

  • 市场展望
    • 母市场
    • 附随市场
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 美国兽医癌症诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 法律规范
    • 以主要类型估算的动物数量（2018-2024 年）
    • COVID-19影响分析

第四章美国兽医癌症诊断市场：按动物类型进行的估计和趋势分析

  • 细分仪表板
  • 美国兽医癌症诊断市场动物类型差异分析
  • 2018-2030年美国兽医癌症诊断市场规模及趋势分析（依动物类型）
    • 狗
    • 猫
    • 其他的

第五章美国兽医癌症诊断市场：按测试类型进行的估计和趋势分析

  • 细分仪表板
  • 美国兽医癌症诊断市场测试类型变化分析
  • 2018-2030 年美国兽医癌症诊断市场规模及趋势分析（依检测类型）
    • 血液检查
    • 切片检查
    • 基因组检测
    • 内视镜检查
    • 尿液检查
    • 影像学诊断

第六章美国兽医癌症诊断市场：按癌症类型进行的估计和趋势分析

  • 细分仪表板
  • 美国兽医癌症诊断市场按癌症类型变化分析
  • 美国兽医癌症诊断市场规模和趋势分析（按癌症类型，2018-2030 年）
    • 淋巴瘤
    • 肉瘤
    • 乳腺肿瘤
    • 皮肤癌
    • 其他的

第七章美国兽医癌症诊断市场：按最终用途的估计和趋势分析

  • 细分仪表板
  • 美国兽医癌症诊断市场最终用途趋势分析
  • 2018-2030 年美国兽医癌症诊断市场规模及趋势分析（依最终用途）
    • 参考实验室
    • 兽医诊所和诊所

第八章竞争格局

  • 市场参与企业分类
  • 参与企业概况
  • 财务表现
  • 产品基准
  • 2024年市场分析（热图分析）
  • 战略地图
    • 合併与收购
    • 发射
    • 伙伴关係和合作
    • 扩张
    • 其他的
  • 公司简介
    • Zoetis
    • Antech Diagnostics, Inc.（Mars Inc.）
    • IDEXX Laboratories, Inc.
    • Neogen Corporation
    • Gold Standard Diagnostics（Eurofins Technologies）
    • Embark Veterinary, Inc.
    • VolitionRx Limited
    • CANCAN DIAGNOSTICS
    • Oncotect
    • PetDx
Product Code: GVR-4-68040-541-6

U.S. Veterinary Oncology Diagnostics Market Growth & Trends:

The U.S. veterinary oncology diagnostics market size is expected to reach USD 1.60 billion by 2030, registering a CAGR of 8.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by growing animal population and ownership rates, increased expenditure on animals, an increasing focus on preventative animal healthcare, and growing partnerships among key players to expand product offerings. For instance, in February 2025, Torigen Pharmaceuticals and Proscia partnered to leverage AI-enabled digital pathology for faster, more accurate cancer diagnoses in pets. This enables quicker, personalized immunotherapy treatments, enhancing survival rates for dogs with metastatic hemangiosarcoma. Torigen's AI-powered diagnostics significantly enhance the accuracy and speed of cancer detection. By delivering results within 3-5 days, it reduces diagnostic turnaround time, allowing veterinarians to begin targeted treatments sooner. This innovation is expected to boost market growth by driving demand for digital pathology solutions in veterinary oncology.

Additionally, advances in veterinary cancer diagnostic testing, and rising R&D investment in animal health diagnostics to launch innovative products are fueling market growth. For instance, in December 2024, Pet Preferred Diagnostics introduced a groundbreaking early cancer diagnostic test for dogs and cats that detects 11 specific onconeural antibodies linked to 21 types of tumors and 14 neurological diseases. This highly sensitive serological test can identify malignancy, often before clinical signs appear, enabling early treatment. It is the only test available in veterinary medicine that differentiates various tumors and neurological conditions, offering a non-invasive, affordable, and quick solution with a 24-hour turnaround.

The rising prevalence of cancer in pets is a key driver of the U.S. veterinary oncology diagnostics market, with 1 in 4 dogs and 1 in 5 cats diagnosed with cancer annually. Increasing pet ownership and humanization trends have boosted demand for advanced diagnostics as pet owners seek early detection and personalized treatments. Technological advancements, such as liquid biopsy tests (e.g., OncoK9 by PetDx) and AI-powered digital pathology (e.g., Torigen and Proscia partnership), are enhancing diagnostic accuracy and efficiency. Additionally, the growing availability of affordable, at-home cancer screening tests (e.g., Oncotect) is making early diagnosis more accessible, further propelling market growth.

U.S. Veterinary Oncology Diagnostics Market Report Highlights:

  • Based on test type, the biopsy segment dominated the market with a share of 28.75% in 2024. However, the genome testing segment is expected to grow at the fastest CAGR of 9.62% during the forecast period due to technological advancements in veterinary cancer diagnostic test kits.
  • Based of animal type, the canine segment attributed to the largest revenue share in 2024 due to the increase in the dog cancer population and the availability of a huge number of products for canine cancer diagnosis. The feline segment is projected to grow at the fastest rate from 2025 to 2030, owing to the rising population of cats worldwide and the apparent rise in the number of associated diseases.
  • Based on cancer type, the skin cancers segment accounted for the highest revenue share in 2024 and is expected to grow at the fastest CAGR of 8.71% owing to the rising prevalence of squamous cell carcinoma and skin tumors in cats and dogs.
  • Based on end use, the veterinary hospitals and clinics segment held the highest revenue share of the market in 2024 owing to the increasing demand for diagnostics and readily accessible advanced veterinary cancer diagnostic technologies in hospitals. This segment is estimated to grow at the fastest CAGR in the coming years.
  • Advances in innovative liquid biopsy and advanced multi-cancer diagnostic technology have led to the development of more accurate, user-friendly, and cost-effective veterinary oncology diagnostic test kits. Such advancements are expected to drive market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Oncology Diagnostics Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of cancer in pets
      • 3.2.1.2. Increasing R&D in veterinary oncolgy diagnostics
      • 3.2.1.3. Growing focus on animal safety
      • 3.2.1.4. Growing uptake of pet insurance
      • 3.2.1.5. Technological advancements in early pet cancer diagnosis
      • 3.2.1.6. Increase in pet population
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of veterinary oncology diagnostics
      • 3.2.2.2. Lack of awareness in developing countries
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Veterinary Oncology Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal Landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental Landscape
    • 3.3.3. Regulatory Framework
    • 3.3.4. Estimated Animal Population, by Key Species, 2018 - 2024
    • 3.3.5. COVID-19 Impact Analysis

Chapter 4. U.S. Veterinary Oncology Diagnostics Market: Animal Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Oncology Diagnostics Market Animal Type Movement Analysis
  • 4.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By Animal Type, 2018 - 2030 (USD Million)
    • 4.3.1. Canine
      • 4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.3.2. Feline
      • 4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.3.3. Others
      • 4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Veterinary Oncology Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Oncology Diagnostics Market Test Type Movement Analysis
  • 5.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By Test Type 2018 - 2030 (USD Million)
    • 5.3.1. Blood Tests
      • 5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.2. Biopsy
      • 5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.3. Genome testing
      • 5.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.4. Endoscopy
      • 5.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.5. Urinalysis
      • 5.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.6. Imaging
      • 5.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Veterinary Oncology Diagnostics Market: Cancer Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Oncology Diagnostics Market Cancer Type Movement Analysis
  • 6.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By Cancer Type, 2018 - 2030 (USD Million)
    • 6.3.1. Lymphoma
      • 6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Sarcomas
      • 6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mammary Gland Tumors
      • 6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.4. Skin Cancers
      • 6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.5. Others
      • 6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Veterinary Oncology Diagnostics Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Veterinary Oncology Diagnostics Market End-Use Movement Analysis
  • 7.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By End-Use 2018 - 2030 (USD Million)
    • 7.3.1. Reference Laboratories
      • 7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Veterinary hospitals and clinics
      • 7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Participants Overview
  • 8.3. Financial Performance
  • 8.4. Product Benchmarking
  • 8.5. Market Position Analysis, 2024 (Heat Map Analysis)
  • 8.6. Strategy Mapping
    • 8.6.1. Mergers and Acquisitions
    • 8.6.2. Launch
    • 8.6.3. Partnerships & Collaborations
    • 8.6.4. Expansion
    • 8.6.5. Others
  • 8.7. Company Profiles
    • 8.7.1. Zoetis
      • 8.7.1.1. Participant's overview
      • 8.7.1.2. Financial performance
      • 8.7.1.3. Product Benchmarking
      • 8.7.1.4. Strategic initiatives
    • 8.7.2. Antech Diagnostics, Inc. (Mars Inc.)
      • 8.7.2.1. Participant's overview
      • 8.7.2.2. Financial performance
      • 8.7.2.3. Product Benchmarking
      • 8.7.2.4. Strategic initiatives
    • 8.7.3. IDEXX Laboratories, Inc.
      • 8.7.3.1. Participant's overview
      • 8.7.3.2. Financial performance
      • 8.7.3.3. Product Benchmarking
      • 8.7.3.4. Strategic initiatives
    • 8.7.4. Neogen Corporation
      • 8.7.4.1. Participant's overview
      • 8.7.4.2. Financial performance
      • 8.7.4.3. Product Benchmarking
      • 8.7.4.4. Strategic initiatives
    • 8.7.5. Gold Standard Diagnostics (Eurofins Technologies)
      • 8.7.5.1. Participant's overview
      • 8.7.5.2. Financial performance
      • 8.7.5.3. Product Benchmarking
      • 8.7.5.4. Strategic initiatives
    • 8.7.6. Embark Veterinary, Inc.
      • 8.7.6.1. Participant's overview
      • 8.7.6.2. Financial performance
      • 8.7.6.3. Product Benchmarking
      • 8.7.6.4. Strategic initiatives
    • 8.7.7. VolitionRx Limited
      • 8.7.7.1. Participant's overview
      • 8.7.7.2. Financial performance
      • 8.7.7.3. Product Benchmarking
      • 8.7.7.4. Strategic initiatives
    • 8.7.8. CANCAN DIAGNOSTICS
      • 8.7.8.1. Participant's overview
      • 8.7.8.2. Financial performance
      • 8.7.8.3. Product Benchmarking
      • 8.7.8.4. Strategic initiatives
    • 8.7.9. Oncotect
      • 8.7.9.1. Participant's overview
      • 8.7.9.2. Financial performance
      • 8.7.9.3. Product Benchmarking
      • 8.7.9.4. Strategic initiatives
    • 8.7.10. PetDx
      • 8.7.10.1. Participant's overview
      • 8.7.10.2. Financial performance
      • 8.7.10.3. Product Benchmarking
      • 8.7.10.4. Strategic initiatives

List of Tables

  • Table. 1 List of Secondary Sources
  • Table. 2 List of Abbreviations
  • Table. 3 U.S. veterinary oncology diagnostics market, by Animal, 2018 - 2030 (USD Million)
  • Table. 4 U.S. veterinary oncology diagnostics market, by Test Type, 2018 - 2030 (USD Million)
  • Table. 5 U.S. veterinary oncology diagnostics market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table. 6 U.S. veterinary oncology diagnostics market, by End-Use, 2018 - 2030 (USD Million)
  • Table. 7 Company Overview
  • Table. 8 Service Benchmarking
  • Table. 9 Financial Performance
  • Table. 10 Strategic Initiatives

List of Figures

  • Fig. 1 U.S. veterinary oncology diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation And Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 General methodology for a commodity flow analysis of U.S. veterinary oncology diagnostics market
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Parent market analysis
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market value, 2024 (USD Billion)
  • Fig. 16 Ancillary market outlook, 2024
  • Fig. 17 U.S. veterinary oncology diagnostics market Dynamics
  • Fig. 18 Estimated animal population, 2018 - 2024 by key species
  • Fig. 19 U.S. veterinary oncology diagnostics market: PORTER's analysis
  • Fig. 20 U.S. veterinary oncology diagnostics market: PESTEL analysis
  • Fig. 21 U.S. veterinary oncology diagnostics market by Animal: Key Takeaways
  • Fig. 22 U.S. veterinary oncology diagnostics market by Animal, 2024 & 2030
  • Fig. 23 Canine market, 2018 - 2030 (USD Million)
  • Fig. 24 Feline market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. veterinary oncology diagnostics market by Test Type: Key Takeaways
  • Fig. 27 U.S. veterinary oncology diagnostics market by Test Type, Market Share, 2024 & 2030
  • Fig. 28 Blood Tests market, 2018 - 2030 (USD Million)
  • Fig. 29 Biopsy market, 2018 - 2030 (USD Million)
  • Fig. 30 Genome testing market, 2018 - 2030 (USD Million)
  • Fig. 31 Endoscopy market, 2018 - 2030 (USD Million)
  • Fig. 32 Urinalysis market, 2018 - 2030 (USD Million)
  • Fig. 33 Imaging market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. veterinary oncology diagnostics market by Cancer Type: Key Takeaways
  • Fig. 35 U.S. veterinary oncology diagnostics market by Cancer Type, Market Share, 2024 & 2030
  • Fig. 36 Lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 37 Sarcomas market, 2018 - 2030 (USD Million)
  • Fig. 38 Mammary Gland Tumors market, 2018 - 2030 (USD Million)
  • Fig. 39 Skin Cancers market, 2018 - 2030 (USD Million)
  • Fig. 40 Others market, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. veterinary oncology diagnostics market by End-Use: Key Takeaways
  • Fig. 42 U.S. veterinary oncology diagnostics market by End-Use, Market Share, 2024 & 2030
  • Fig. 43 Reference Laboratories market, 2018 - 2030 (USD Million)
  • Fig. 44 Veterinary hospitals and clinics market, 2018 - 2030 (USD Million)
  • Fig. 45 Market Participant Categorization
  • Fig. 46 Heat map analysis
  • Fig. 47 Strategic Framework